|
|
|
|
|
|
Sponsors and Collaborators: |
Second Sight Medical Products National Institutes of Health (NIH) |
Information provided by: | Second Sight Medical Products |
ClinicalTrials.gov Identifier: | NCT00407602 |
The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with severe to profound retinitis pigmentosa.
Condition | Intervention | Phase |
Retinitis Pigmentosa |
Device: Argus II Retinal Stimulation System |
Phase II |
Genetics Home Reference related topics: | Lenz microphthalmia syndrome oculofaciocardiodental syndrome Peters plus syndrome X-linked juvenile retinoschisis |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Argus™ II Retinal Stimulation System Feasibility Protocol |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Optic Nerve disease
Diseases or conditions that effect retinal function including but not limited to:
Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including:
United States, California | |||||
Doheny Eye Institute | Active, not recruiting | ||||
Los Angeles, California, United States, 90033 | |||||
University of California San Francisco | Active, not recruiting | ||||
San Francisco, California, United States, 94143 | |||||
United States, Maryland | |||||
Johns Hopkins, Wilmer Eye Institute | Active, not recruiting | ||||
Baltimore, Maryland, United States, 21205 | |||||
United States, New York | |||||
Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute | Active, not recruiting | ||||
New York, New York, United States, 10032 | |||||
United States, Texas | |||||
Retina Foundation of the Southwest | Active, not recruiting | ||||
Dallas, Texas, United States, 75231 | |||||
France | |||||
Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12 | Recruiting | ||||
Paris, France | |||||
Contact: Saddek Mohand-Said, MD +33 1 40 02 14 31 mohand@quinze-vingts.fr | |||||
Contact: Jeanne Haidar +33 1 40 02 14 57 jhaidar@cicoph.org | |||||
Principal Investigator: Jose Sahel, MD | |||||
Sub-Investigator: Saddek Mohand Said, MD | |||||
Mexico, Jalisco | |||||
Puerta de Hierro, Centro Medico, Centro de Retina | Recruiting | ||||
Zapopan, Jalisco, Mexico, 51116 | |||||
Contact: Arturo Santos Garcia, MD +52 (33) 3848-5468 | |||||
Principal Investigator: Arturo Santos Garcia, MD | |||||
Sub-Investigator: Enrique Roig Melo-Granados, MD | |||||
Switzerland | |||||
Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205 | Recruiting | ||||
Geneva, Switzerland | |||||
Contact: Joel Salzmann, MD +41 22 382 84 89 Joel.Salzmann@hcuge.ch | |||||
Contact: Jorg Sommerhalder +41 22 382 84 20 jorg.r.sommerhalder@hcuge.ch | |||||
Principal Investigator: Avinoam Safran, MD | |||||
Sub-Investigator: Joel Salzmann, MD | |||||
Sub-Investigator: Marco Pelizzone, PhD. | |||||
Sub-Investigator: Jorg Sommerhalder, PhD | |||||
Sub-Investigator: Angelica P Perez Fornos, PhD | |||||
United Kingdom | |||||
Moorfields Eye Hospital, Vitreoretinal Research Unit | Recruiting | ||||
City Road, London, United Kingdom, EC1V 2PD | |||||
Contact: Lyndon daCruz, M.D. +44 (0)20 7566 2251 Lyndon.daCruz@moorfields.nhs.uk | |||||
Contact: Andrew Webster, MD +44 0(20) 7566 2255 Andrew.webster@ucl.ac.uk | |||||
Principal Investigator: Lyndon daCruz, MD | |||||
Sub-Investigator: Andrew Webster, MD |
Second Sight Medical Products |
National Institutes of Health (NIH) |
Study ID Numbers: | CP-003-001 |
First Received: | December 1, 2006 |
Last Updated: | August 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00407602 |
Health Authority: | United States: Food and Drug Administration |
|
|
|